Skip to main content
. 2022 Jul 23;113(9):3169–3179. doi: 10.1111/cas.15474

FIGURE 4.

FIGURE 4

Time to deterioration in Functional Assessment of Cancer Therapy – Breast Trial Outcome Index (intention‐to‐treat population) among women with HER2‐positive advanced breast cancer treated with pertuzumab + trastuzumab + chemotherapy (PTC) or trastuzumab + chemotherapy (TC). CI, confidence interval; HR, hazard ratio